U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT06969807) titled 'Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease' on April 24.
Brief Summary: This trial is to evaluate the efficacy and safety of umbilical cord-derived mesenchymal stromal cells (Amimestrocel ) in study subjects with progressive diabetic kidney disease (DKD), to investigate whether Amimestrocel can improve renal function or proteinuria of DKD patients.
Study Start Date: May 15
Study Type: INTERVENTIONAL
Condition:
Diabetic Kidney Disease (DKD)
Intervention:
DRUG: Amimestrocel
In the first month (day 1, 14, 28): 1x10E6 cells per kilogram. From the 8th to the 24th week (week 8, 12, 16...